Refiners Continue T...
Health Care: Drugs
Puma Biotechnology Inc (PBYI: NYSE)
$38.41 -0.14 | -0.36%
05/24/13 - 04:02 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 137.41M | 53.38M | 462.00 | 2.41K |
| Receivables | 10.61M | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 148.97M | 53.66M | 462.00 | 2.41K |
| Property, Plant & Equipment, Gross | 1.76M | 692.76K | 0.00 | 0.00 |
| Accumulated Depreciation & Depletion | 276.00K | 10.70K | 0.00 | 0.00 |
| Property, Plant & Equipment, Net | 1.48M | 682.05K | 0.00 | 0.00 |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 1.25M | 1.05M | 0.00 | 0.00 |
| Total Non-Current Assets | 2.73M | 1.74M | 0.00 | 0.00 |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 151.70M | 55.40M | 462.00 | 2.41K |
| Accounts Payable | 482.00K | 86.67K | 0.00 | 2.27K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 21.70M | 586.21K | 0.00 | 2.27K |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 1.09M | 439.42K | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 1.09M | 439.42K | 0.00 | 0.00 |
| Total Liabilities | 22.79M | 1.03M | 0.00 | 2.27K |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 128.91M | 54.37M | 462.00 | 138.00 |
| Common Par | 3.00K | 2.00K | 300.00 | 300.00 |
| Additional Paid In Capital | 213.50M | 64.61M | 62.15K | 45.85K |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -84.59M | -10.24M | -61.99K | -46.01K |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 128.91M | 54.37M | 462.00 | 138.00 |
| Total Equity | 128.91M | 54.37M | 462.00 | 138.00 |
| Total Liabilities & Stock Equity | 151.70M | 55.40M | 462.00 | 2.41K |
| Total Common Shares Outstanding | 28.68M | 20.04M | 20.04M | 20.04M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 21.73M | 7.75M | 3.00M | 3.00M |
| Diluted Weighted Shares Outstanding | 21.73M | 7.75M | 3.00M | 3.00M |
| Number of Employees | 49 | 18 | NA | NA |
| Number of Part-Time Employees | 0 | 0 | NA | NA |
Portfolios with PBYI
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
Latest PBYI Headlines from TheStreet
- 3 Stocks Spiking on Big Volume 04.15.13 | 02:04 pm
- Top Insider Trades: NSH PBYI CONN EPHC 12.12.12 | 09:12 am
- Insiders Trading BLK FIRE SONS PBYI 10.23.12 | 09:10 am
- Insiders Trading NCT, PBYI, NAV, OPK 07.30.12 | 01:07 pm
- Insiders Trading FDO, PBYI, SUMR, ENTG 07.19.12 | 09:07 am
- Top Insider Trades: SPB PBYI GPK AXS 12.31.69 | 07:12 pm
Press Releases for PBYI
- Puma Biotechnology To Present At Cowen Healthcare Conference - Business Wire 02.26.13 | 08:02 am
- Puma Biotechnology Announces Agreement With FDA On Special Protocol Assessment For Phase III Trial Of PB272 (Neratinib) In HER2-Positive Metastatic Breast Cancer Patients - Business Wire 02.20.13 | 08:02 am
- Puma Biotechnology To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 08:02 am
- Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data At CTRC-AACR San Antonio Breast Cancer Symposium - Business Wire 12.07.12 | 06:12 pm
- Puma Biotechnology Reports Third Quarter 2012 Financial Results - Business Wire 11.14.12 | 08:11 am
- Puma Biotechnology To Present At Lazard Healthcare Conference - Business Wire 11.07.12 | 08:11 am
- Puma Biotechnology Closes $138 Million Public Offering Of Common Stock - Business Wire 10.24.12 | 02:10 pm
- Puma Biotechnology Announces Underwriters’ Full Exercise Of Overallotment Option, Increasing Total Offering Size To $138 Million - Business Wire 10.22.12 | 08:10 am
- Puma Biotechnology Announces Upsizing And Pricing Of $120 Million Public Offering Of Common Stock - Business Wire 10.18.12 | 06:10 pm
- Puma Biotechnology To Present At UBS Global Life Sciences Conference - Business Wire 09.12.12 | 08:09 am
Partner Headlines for PBYI
- Analysts: CarMax Can Maintain Momentum and 3 New Opinions Investors Must Take a Peek At - Wall St. Cheat Sheet 04.02.13 | 11:04 am
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
